An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Latest Information Update: 17 Aug 2023
At a glance
- Drugs Eteplirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sarepta Therapeutics
- 14 Sep 2021 According to a Sarepta Therapeutics media release, data from this study will present at the World Muscle Society 2021 Virtual Congress (WMS 2021)
- 08 Apr 2021 Status changed from active, no longer recruiting to completed.
- 22 Nov 2019 Status changed from recruiting to active, no longer recruiting.